BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin
BiomX Inc. COmmon Stock (PHGE)
Company Research
Source: Business Wire
- Primary endpoints are safety and tolerability - Exploratory endpoints include proof of principle by measurement of C. acnes skin levels- Clinical data are expected at the end of the first quarter of 2020 NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies, today announced that patient recruitment for its cosmetic clinical study of BX001, initiated on Oct. 1, 2019, is complete and that 75 patients have been recruited. BX001 is a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes, formerly taxonomically classified as Propionibacterium acnes, or P. acnes), a bacterium implicated in the pathophysiology of acne vulgaris. The primary endpoints of the randomized, double-blind, dose-ranging, vehicle-controlled study are safety and tolerability. Exploratory endpoints include proof of principle by measurement of the effect of BX001 o
Show less
Read more
Impact Snapshot
Event Time:
PHGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHGE alerts
High impacting BiomX Inc. COmmon Stock news events
Weekly update
A roundup of the hottest topics
PHGE
News
- Microbiome Sequencing Services Business Report 2024-2030: Strong Investment in Genomics Research Crucial for Market Growth [Yahoo! Finance]Yahoo! Finance
- Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI [Yahoo! Finance]Yahoo! Finance
- BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net Income Amid Rising Expenses [Yahoo! Finance]Yahoo! Finance
- BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates [Yahoo! Finance]Yahoo! Finance
- BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program UpdatesGlobeNewswire
PHGE
Earnings
- 11/14/24 - Beat
PHGE
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/13/24 - Form SCHEDULE
- PHGE's page on the SEC website